NEWS
In case you were wondering, here's a guide to the carb
count of your coffee, courtesy of www.beyondtype1.com
NOVO
NORDISK
BUYS ZIYLO
Dr Harry Destecroix, 31, co-founded Ziylo
while studying for his PhD at the University
of Bristol four years ago. It created a new
technology that can be developed to treat
diabetes more effectively. Pharmaceutical
giant Novo Nordisk's purchase means it
now has full rights to develop glucose
responsive insulins, as reported by the
BBC. Destecroix said he hoped the sale
will offer ground-breaking treatment for
diabetics. Ziylo, a university spin-out
company, developed a synthetic molecule
which works by binding glucose in the
bloodstream more effectively. Danish
firm Novo Nordisk, one of the biggest
manufacturers of diabetes medicines, will
now aim to use this molecule to develop
a new type of insulin which aims to help
diabetics manage their condition more
safely. www.bbc.co.uk/ziylo
NATHALIE BALMAIN DEXCOM VIDEO